Stock Track | Hims & Hers Health Soars 5.33% in Pre-market on Strategic Overhaul and Novo Nordisk Collaboration

Stock Track03-12

Hims & Hers Health Inc. (HIMS) saw its stock price surge 5.33% during pre-market trading on Thursday, following a major strategic announcement from the company.

The telehealth company revealed a significant overhaul of its U.S. weight loss business, centered on a new collaboration with pharmaceutical giant Novo Nordisk. As part of this strategic shift, Hims & Hers plans to expand access to a broader assortment of FDA-approved GLP-1 medications, including Ozempic and Wegovy injections and tablets, on its platform later this month.

Concurrently, the company will limit the availability of compounded semaglutide, stop advertising these offerings, and aims to transition existing patients to FDA-approved options when clinically appropriate. This move aligns its U.S. operations with its global model and is expected to strengthen its position in the competitive weight-loss treatment market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148115721?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 16:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148115721","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5.33% in Pre-market on Strategic Overhaul and Novo Nordisk Collaboration","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) saw its stock price surge 5.33% during pre-market trading on Thursday, following a major strategic announcement from the company.</p><p>The telehealth company revealed a significant overhaul of its U.S. weight loss business, centered on a new collaboration with pharmaceutical giant Novo Nordisk. As part of this strategic shift, Hims & Hers plans to expand access to a broader assortment of FDA-approved GLP-1 medications, including Ozempic and Wegovy injections and tablets, on its platform later this month.</p><p>Concurrently, the company will limit the availability of compounded semaglutide, stop advertising these offerings, and aims to transition existing patients to FDA-approved options when clinically appropriate. This move aligns its U.S. operations with its global model and is expected to strengthen its position in the competitive weight-loss treatment market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5.33% in Pre-market on Strategic Overhaul and Novo Nordisk Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5.33% in Pre-market on Strategic Overhaul and Novo Nordisk Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-12 16:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) saw its stock price surge 5.33% during pre-market trading on Thursday, following a major strategic announcement from the company.</p><p>The telehealth company revealed a significant overhaul of its U.S. weight loss business, centered on a new collaboration with pharmaceutical giant Novo Nordisk. As part of this strategic shift, Hims & Hers plans to expand access to a broader assortment of FDA-approved GLP-1 medications, including Ozempic and Wegovy injections and tablets, on its platform later this month.</p><p>Concurrently, the company will limit the availability of compounded semaglutide, stop advertising these offerings, and aims to transition existing patients to FDA-approved options when clinically appropriate. This move aligns its U.S. operations with its global model and is expected to strengthen its position in the competitive weight-loss treatment market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1148115721","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148115721","pubTimestamp":1773302710,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) saw its stock price surge 5.33% during pre-market trading on Thursday, following a major strategic announcement from the company.The telehealth company revealed a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘前大涨5.33%因战略改革与诺和诺德合作","themeId":"c0d45a5d5c22be184a8c03cead54ecb1","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) saw its stock price surge 5.33% during pre-market trading on Thursday, following a major strategic announcement from the company.The telehealth company revealed a significant overhaul of its U.S. weight loss business, centered on a new collaboration with pharmaceutical giant Novo Nordisk. As part of this strategic shift, Hims & Hers plans to expand access to a broader assortment of FDA-approved GLP-1 medications, including Ozempic and Wegovy injections and tablets, on its platform later this month.Concurrently, the company will limit the availability of compounded semaglutide, stop advertising these offerings, and aims to transition existing patients to FDA-approved options when clinically appropriate. This move aligns its U.S. operations with its global model and is expected to strengthen its position in the competitive weight-loss treatment market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148115721","isCrawlerRequest":true}